Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness.
Aducanumab, to be sold under the brand name Aduhelm, was approved to treat patients with Alzheimer’s disease — against the recommendation of an FDA advisory committee that concluded last year there is not enough evidence to support approval of the treatment. The FDA has not approved a novel therapy for Alzheimer’s disease since 2003.
Patients now have many questions about…
